Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Pfizer presented data ​on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its purchase of Metsera last year had a similar side-effect profile as rival Novo Nordisk's weekly injection Wegovy.